TSXV:XRTX - Post Discussion
Post by
waves1 on Mar 15, 2024 4:58pm
New Patent for Treatment of Chronic Kidney Disease Submitted
Late-stage clinical pharmaceutical and drug-based biotechnology company XORTX Therapeutics (NASDAQ/TSXV: XRTX) is developing innovative therapies to improve the quality of life of patients with progressive kidney disease and diabetes.
As detailed by Alliance Global Partners latest research report, XRTX is focused on revolutionary technology for large markets such as diabetic nephropathy and acute kidney injury associated with respiratory virus infections.
XRTX possesses patents and patent applications including US and international rights regarding the development of uric acid-lowering agents for the treatment of hypertension, insulin resistance, diabetes, metabolic syndrome, and kidney injury.
Recently, XRTX announced the submission of a new patent for the treatment of chronic kidney disease (CKD) for new formulations of xanthine oxidase inhibitors (XOI) for their use in particular autosomal dominant polycystic kidney diseases (ADPKD), diabetic nephropathy (DN), IgA nephropathy, lupus nephritis and focal segmental glomerulosclerosis.
Marking a positive step in XRTX's pipeline, this patent comes in addition to its Xorlo program which is in a Phase 2/3 trial in patients with stage 2-4 ADPKD.
XRTX is continuing to scale up its supply and to conduct pre-launch activities in prep for a potential NDA filing as soon as 2025.
With the potential for Xorlo to be the next potential ADPKD treatment option available, Alliance Global Partners reiterated its BUY rating and raised its price target to $14/share based on a sum-of-the-parts analysis and the underlying technology.
Be the first to comment on this post